SC10914

SC10914 is an orally bioavailable small molecule inhibitor of the nuclear enzymes poly(ADP-ribose) polymerase (PARP) 1 and PARP2. By selectively binding to and inhibiting PARP-1 and PARP-2 enzymes in tumor cells, it prevents DNA repair mediated by these proteins. This leads to accumulation of DNA damage and ultimately induces cell death in cancer cells that rely on PARP-mediated repair mechanisms. The drug is structurally similar to olaparib and is being developed primarily for the treatment of cancers with defects in homologous recombination repair pathways such as BRCA-mutated breast cancer and ovarian cancer. It has been evaluated in phase I/II clinical trials for advanced solid tumors including breast cancer (especially BRCA mutation positive), ovarian serous tumor/cancer (including fallopian tube and peritoneal cancers), metastatic castration-resistant prostate cancer as well as other neoplasms[1][2][3][4][5].

Other names

SC10914SC-10914SC 10914DN-1DN1DN 1